EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

LAG3, TIM3 and TIGIT: New Targets for Immunotherapy and Potential Associations with Radiotherapy

Camil Ciprian Mireștean iD, Roxana Irina Iancu, Dragoș Petru Teodor Iancu

Current Oncology · 2025

DOI: 10.3390/curroncol32040230 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, 2025. Verfasst von Camil Ciprian Mireștean und 2 weiteren Autor:innen. Beteiligte Einrichtung: Regional Institute of Oncology, 700483 Iasi, Romania. Hauptthemen laut MEDLINE: Immunotherapy, Hepatitis A Virus Cellular Receptor 2, Neoplasms, Receptors, Immunologic. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The combination of immunotherapy and radiotherapy has demonstrated synergistic potential, especially when a combination of immune checkpoint inhibitors (ICIs) is administered. Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4) inhibitors and Programmed Death-Ligand 1 (PD-L1) inhibitors or Programmed Cell Death Protein 1 (PD-1) inhibitors have been assessed in both clinical and preclinical studies; the addition of radiotherapy activates immunomodulatory mechanisms materialized by an effect similar to “in situ” vaccination or the “abscopal” distant response of lesions outside the irradiation field. The new therapeutic targets (T cell immune-receptor with Ig and ITIM domains (TIGIT), Lymphocyte activating gene 3 (LAG-3), and T cell Ig- and mucin-domain-containing molecule-3 (TIM-3)) associated with traditional ICIs and radiotherapy open new perspectives to the concept of immuno-radiotherapy. The dynamic evaluation of T lymphocyte expression involved in the antitumor immune response, both in the tumor microenvironment (TME) and in the tumor itself, could have biomarker value in assessing the response to combination therapy with traditional and new ICIs in association with irradiation. Preclinical data justify the initiation of clinical trials in various tumor pathologies to explore this concept.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyHepatitis A Virus Cellular Receptor 2NeoplasmsReceptors, ImmunologicAntigens, CDHumansLymphocyte Activation Gene 3 ProteinRadiotherapyTumor MicroenvironmentImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

CTLA-4ICILAG-3PD-1PD-L1SRSTIGITTIM-3immunotherapyradiotherapysynergy

Substanzen

TIGIT protein, humanHepatitis A Virus Cellular Receptor 2HAVCR2 protein, humanLymphocyte Activation Gene 3 ProteinReceptors, ImmunologicAntigens, CDLag3 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Regional Institute of Oncology, 700483 Iasi, Romania.
  • "Gr. T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
  • "St. Spiridon" Emergency Universitary Hospital, 700111 Iasi, Romania.

ORCID-Profile: Camil Ciprian Mireștean

Zitieren

APA

Mireștean, C. C., Iancu, R. I., & Iancu, D. P. T. (2025). LAG3, TIM3 and TIGIT: New Targets for Immunotherapy and Potential Associations with Radiotherapy. Current Oncology. https://doi.org/10.3390/curroncol32040230

Vancouver

Mireștean CC, Iancu RI, Iancu DPT. LAG3, TIM3 and TIGIT: New Targets for Immunotherapy and Potential Associations with Radiotherapy. Current Oncology. 2025. doi:10.3390/curroncol32040230

BibTeX
@article{Miretean2025,
  author = {Mireștean, Camil Ciprian and Iancu, Roxana Irina and Iancu, Dragoș Petru Teodor},
  title = {LAG3, TIM3 and TIGIT: New Targets for Immunotherapy and Potential Associations with Radiotherapy},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32040230}
}
Kostenlos starten →